Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dose-escalation Trial of OMTX705, an Anti-fibroblast Activation Protein Antibody-drug Conjugate, as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

Phase 1 Dose-escalation Trial of OMTX705, an Anti-fibroblast Activation Protein Antibody-drug Conjugate, as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OMTX 705 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Leiomyosarcoma; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic ductal carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Oncomatryx

Most Recent Events

  • 15 Jul 2025 According to an Oncomatryx media release, the company has been awarded funding from the European Innovation Council (EIC) Accelerator under the EU's Horizon Europe 2021-2027 Research and Innovation Program. Oncomatryx will receive euros 2.5 million in grant funding, along with a euros 10 million equity investment, funding will enable us to advance the expansion cohorts of our ongoing Phase I clinical trial in pancreatic, colorectal, and lung cancer.
  • 22 Feb 2023 Status changed from not yet recruiting to recruiting.
  • 16 Sep 2022 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top